Pfizer's biosimilar shows similarity to Avastin

25 July 2017
biosimilars_samples_large

US drug giant Pfizer (NYSE: PFE) has moved closer to market with its biosimilar version of Roche’s (ROG: SIX) Avastin (bevacizumab).

Pfizer has announced positive top-line results from a study comparing its biosimilar, PF-06439535, to the original, which was the world’s second-best selling cancer drug last year with sales of nearly $7 billion.

At present, US biotech Amgen (Nasdaq: AMGN) and Ireland-incorporated drugmaker Allergan (NYSE: AGN) are furthest ahead with an Avastin biosimilar, having had their candidate, ABP 215, recommended for approval by a US Food and Drug Administration (FDA) committee this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars